Cell-based Cancer Immunotherapy

1. Methods behind clinical DC vaccine products against glioblastoma<br>Rüdiger V. Sorg<br>2. Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy<br>Jolanda de Vries and Gerty Schreibelt<br>3. Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients<br>Stefaan W. Van Gool<br>4. Identification of TCR repertoire patterns linked with anti-cancer immunotherapy<br>Kris Laukens and Romi Vandoren<br>5. Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells<br>Eva Lion and Kris Laukens<br>6. Methods behind neoantigen predictions for anticancer vaccines<br>Cedric Bogaert<br>7. Methods behind CD137L-DC-EBV-VAX anticancer vaccine<br>Herbert Schwarz<br>8. Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies<br>Dmitri Krysko<br>9. Methods behind TCR analyses for colorectal cancer-associated TILs<br>Sara Verbandt, Ting Pu and Sabine Tejpar<br>10. The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays<br>Adam Snook<br>11. Humanized mouse models for anti-cancer therapy<br>Eleonora Leucci<br>12. In vitro re-challenge of CAR T cells<br>Sebastien Walchli and Alicia Villatoro<br>13. Methods behind adoptively transferred tumor draining lymphocytes​ for anticancer immunotherapy<br>Harry D. Bear and Carolyn Haynes<br>14. A murine glioblastoma platform to test cellular therapies with the standard of care<br>An Coosemans and Aaron Ziani Zeryouh Jr.